Skip to Content

Becton Dickinson & Co

BDX: XNYS (USA)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
$415.00XlyzqhtZgtzhzb

Strong Veritor Demand Sets BD for Strong 2021

Business Strategy and Outlook

2020 was a challenging year for Becton, Dickinson, or BD. While the company had seen a modest uptick in revenue related to the coronavirus pandemic, many of its business lines tied to hospital admissions got crushed. In addition, BD suffered from a major self-inflicted wound--a recall of its infusion pump Alaris. Combined with a paclitaxel setback to its vascular portfolio from a prior year, the company's execution has been far from ideal.

Free Trial of Morningstar Investor

Get our analysts’ objective, in-depth, and continuous investment coverage of BDX so you can make buy / sell decisions free of market noise.

Start Free Trial

Sponsor Center